Clinical Trial Update: Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating nadofaragene firadenovec delivered to the renal pelvis for low-grade upper tract urothelial carcinoma is currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Upper Tract Urothelial Carcinoma

Drugs mentioned

• Nadofaragene firadenovec (nadofaragene firadenovec)

Snippet

Sponsor: Ferring Pharmaceuticals | Conditions: Low-grade Upper Tract Urothelial Carcinoma | Phase 1, Phase 2 | Status: RECRUITING